Exchange: TSXV·Updated 03:59 PM EDT

About ARCH.TSXV

About

Arch Biopartners, Inc. is a therapeutic biotech company developing novel, on-target drugs for kidney injury and disease. Its portfolio includes programs in both acute kidney injury (AKI) and chronic kidney disease (CKD), two serious conditions that affect hundreds of millions of patients worldwide. Arch's drug candidates, LSALT peptide and Cilastatin, are in Phase II clinical trials and have the potential to significantly improve outcomes for patients at risk of AKI. The company is also advancing its pre-clinical CKD platform targeting IL-32, a non-classical cytokine directly implicated in diabetic kidney disease, the main cause of kidney failure worldwide. The company was founded by Richard Gabriel Muruve and Daniel Muruve on March 4, 1983 and is headquartered in Toronto, Canada.
Sector:
Health Technology
Industry:
Pharmaceuticals Major
Employees:
N/A

Frequently Asked Questions

What is Market Cap of Arch Biopartners Inc.?
What is the 52-week high for Arch Biopartners Inc.?
What is the 52-week low for Arch Biopartners Inc.?
What is Arch Biopartners Inc. stock price today?
What was Arch Biopartners Inc. stock price yesterday?
What is the PE ratio of Arch Biopartners Inc.?
What is the Price-to-Book ratio of Arch Biopartners Inc.?
What is the 50-day moving average of Arch Biopartners Inc.?

Advertisement|Remove ads.